Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.52 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.52 |
| ▸ | GABRP | O00591 | 1/20 | 0.52 |
| ▸ | GABRD | O14764 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.52 |
| ▸ | GABRE | P78334 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.52 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.52 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.52 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27840525 | 0.94 | GABRP (0.46) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL22053158 | 0.90 | TSHR (0.43) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL27712231 | 0.88 | MEN1 (0.45) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL25015448 | 0.86 | — | — | |
| SCHEMBL24073181 | 0.86 | — | — | |
| SCHEMBL14218506 | 0.86 | — | — | |
| SCHEMBL256670 | 0.84 | — | — | |
| SCHEMBL3949885 | 0.82 | GABRP (0.48) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| Fluorobenzene SCHEMBL27513887 | 0.81 | SLC6A2 (0.40) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| Hydrochloric Acid SCHEMBL20508301 | 0.80 | GNAI3 (0.49) | GABRA1TSHRGABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101795689-B | Positive allosteric modulators of benzamide mGluR5 and methods of making and using the same | UNIV VANDERBILT | 2014-11-19 | — | — | CN | claimed |
| US-20260103451-A1 | PROCESS FOR PREPARING PYRIMIDINYL BIPYRIDINE COMPOUND AND INTERMEDIATE THEREFOR | BEYONDBIO INC (KR) | 2026-04-16 | — | — | US | disclosed |
| US-12371418-B2 | Process for preparing pyrimidinyl bipyridine compound and intermediate therefor | BEYONDBIO INC. (KR) | 2025-07-29 | — | — | US | disclosed |
| WO-2024240242-A1 | COMPOUND CONTAINING AMIDE-SUBSTITUTED AROMATIC RING, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 正大天晴药业集团股份有限公司 | 2024-11-28 | — | — | WO | disclosed |
| CN-114364671-B | Process for preparing pyrimidinyl bipyridine compounds and intermediates therefor | BEYONDBIO株式会社 | 2024-08-02 | — | — | CN | disclosed |
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-04-27 | — | — | US | disclosed |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220324839-A1 | PROCESS FOR PREPARING PYRIMIDINYL BIPYRIDINE COMPOUND AND INTERMEDIATE THEREFOR | BEYONDBIO INC. (KR) | 2022-10-13 | — | — | US | disclosed |
| CN-115043773-A | Synthesis method of 4-N-tert-butyloxycarbonyl-1- (3-methoxypropyl) -4-piperidinamine | 山东新时代药业有限公司 | 2022-09-13 | — | — | CN | disclosed |
| EP-4029861-A1 | METHOD FOR PRODUCING PYRIMIDINYL BIPYRIDINE COMPOUND AND INTERMEDIATE THEREFOR | Beyondbio Inc. (KR) | 2022-07-20 | — | — | EP | disclosed |
| EP-1919907-A2 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-6191145-B1 | ANTICOAGULANTS; ANTIINFLAMMATORY AGENTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-02-20 | — | — | US | disclosed |
| EP-1028943-A2 | ORALLY-ACTIVE NIPECOTAMIDE GLYCOLAMIDE ESTERS FOR THE TREATMENT OF THROMBOSIS DISORDERS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| US-6066651-A | ANTITHROMBOTIC AGENTS BY VIRTUE OF THEIR ABILITY TO PREVENT PLATELET AGGREGATION | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-05-23 | — | — | US | disclosed |
| WO-1999021832-A2 | ORALLY-ACTIVE NIPECOTAMIDE GLYCOLAMIDE ESTERS FOR THE TREATMENT OF THROMBOSIS DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| US-5661148-A | ANTIHYPOXIC AGENT FOR RESPIRATORY SYSTEM DISORDER | TEIJIN LIMITED (JP) | 1997-08-26 | — | — | US | disclosed |
| EP-0514540-B1 | PYRROLO 2,3-d]PYRIMIDINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL PREPARATION COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LTD (JP) | 1996-07-17 | — | — | EP | disclosed |
| EP-0514540-A1 | PYRROLO 2,3-d]PYRIMIDINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL PREPARATION COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1992-11-25 | — | — | EP | disclosed |
| US-3970656-A | ANALGESIC | GOVERNMENT OF THE UNITED STATES (US) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103451-A1 | PROCESS FOR PREPARING PYRIMIDINYL BIPYRIDINE COMPOUND AND INTERMEDIATE THEREFOR | CCND1, CCND2, CDK2 | GABRA1 3071/4885TSHR 2561/4885GABRG2 3054/4885 |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | GABRA1 2520/4885TSHR 4288/4885GABRG2 1919/4885 |
| US-20220324839-A1 | PROCESS FOR PREPARING PYRIMIDINYL BIPYRIDINE COMPOUND AND INTERMEDIATE THEREFOR | WEE1, GGPS1, WEE2 | GABRA1 393/4885TSHR 4689/4885GABRG2 471/4885 |
| US-12371418-B2 | Process for preparing pyrimidinyl bipyridine compound and intermediate therefor | WEE1, GGPS1, WEE2 | GABRA1 393/4885TSHR 4689/4885GABRG2 471/4885 |
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNK3 | GABRA1 374/4885TSHR 2184/4885GABRG2 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.